Fachbereich Chemie
Publikationen von Peter Heisig
| Suche: FB Chemie / Hamburg | |
| 2023 | |
| 105 |
Synthesis, biological evaluation, and molecular docking studies of aldotetronic acid-based LpxC inhibitors Stefan Wimmer, Katharina Hoff, Benedikt Martin, Martin Grewer, Laura Denni, Raquel Lascorz Massanet, Maria Valeria Raimondi, Emre F. Bülbül, Jelena Melesina, Sven-Kevin Hotop, Jörg Haupenthal, Holger Rohde , Peter Heisig, Anna K. H. Hirsch, Mark Brönstrup, Wolfgang Sippl, Ralph Holl Bioorganic Chemistry 131, 106331 (2023) |
| 104 |
Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles Jan-Niklas Eckardt, Christoph Röllig, Klaus Metzeler, Peter Heisig, Sebastian Stasik, Julia-Annabell Georgi, Frank Kroschinsky, Friedrich Stölzel, Uwe Platzbecker, Karsten Spiekermann, Utz Krug, Jan Braess, Dennis Görlich, Cristina Sauerland, Bernhard Woermann, Tobias Herold, Wolfgang Hiddemann, Carsten Müller-Tidow, Hubert Serve, Claudia D. Baldus, Kerstin Schäfer-Eckart, Martin Kaufmann, Stefan W. Krause, Mathias Hänel, Wolfgang E. Berdel, Christoph Schliemann, Jiri Mayer, Maher Hanoun, Johannes Schetelig, Karsten Wendt, Martin Bornhäuser, Christian Thiede, Jan Moritz Middeke Communications Medicine 3, 68 (2023) |
| 103 |
Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning. Jan-Niklas Eckardt, Christoph Röllig, Klaus Metzeler, Michael Kramer, Sebastian Stasik, Julia-Annabell Georgi, Peter Heisig, Karsten Spiekermann, Utz Krug, Jan Braess, Dennis Görlich, Cristina M. Sauerland, Bernhard Woermann, Tobias Herold, Wolfgang E. Berdel, Wolfgang Hiddemann, Frank Kroschinsky, Johannes Schetelig, Uwe Platzbecker, Carsten Müller-Tidow, Tim Sauer, Hubert Serve, Claudia Baldus, Kerstin Schäfer-Eckart, Martin Kaufmann, Stefan Krause, Mathias Hänel, Christoph Schliemann, Maher Hanoun, Christian Thiede, Martin Bornhäuser, Karsten Wendt, Jan Moritz Middeke Haematologica 108, 690-704 (2023) |
2021 | |
| 102 |
Antibacterial activity of xylose-derived LpxC inhibitors - Synthesis, biological evaluation and molecular docking studies Alexander Dreger, Katharina Hoff, Oriana Agoglitta, Sven-Kevin Hotop, Mark Brönstrup, Peter Heisig, Johannes Kirchmair , Ralph Holl Bioorganic Chemistry 107, 104603 (15 pp) (2021) |
2020 | |
| 101 |
Bacterial Resistance to Antibiotics Anke Heisig, Peter Heisig -/- Herausgeber: Stefan Offermanns, Walter Rosenthal Encyclopedia of Molecular Pharmacology Online: 01 June 2020 (17 pp) (2020) |
2019 | |
| 100 |
Arzneibuchkommentar - Wissenschaftliche Erläuterungen zum Europäischen und Deutschen Arzneibuch Herausgeber: Franz Bracher, Peter Heisig, Peter Langguth, Ernst Mutschler, Gerhard Rücker, Tanja Schirmeister, Gerhard Scriba, Gunther Seitz, Elisabeth Stahl-Biskup, Reinhard Troschütz Loseblatt-Ausgabe und DVD-ROM-Ausgabe plus; 1. Auflage einschließlich 60. Aktualisierungs-Lieferung (2019), Verlag: Wissenschaftliche Verlagsgesellschaft, Stuttgart |
2018 | |
| 99 |
Update Antibiotikaresistenz: Entstehung, Epidemiologie, Wirkstoffentwicklung Herausgeber: Peter Heisig Seiten: 114 pp, ISBN 978-3-7692-7113-3, Verlag: Deutscher Apotheker Verlag (2018) |
| 98 |
Antibiotikaresistenz - Mechanismen der Entstehung und Ausbreitung Peter Heisig Update Antibiotikaresistenz: Entstehung, Epidemiologie, Wirkstoffentwicklung 1-17 (2018), ISBN 978-3-7692-7113-3 , Verlag: Deutscher Apotheker Verlag |
2017 | |
| 97 |
Protecting Group Free Total Syntheses of Rubrolide R and S Mathias Schacht, Gordon Jacob Boehlich, Jessica de Vries, Stephanie Bertram, Gülsah Gabriel, Phyllis Zimmermann, Peter Heisig, Nina Schützenmeister European Journal of Organic Chemistry 1745-1748 (2017) |
2016 | |
| 96 |
The Emergence of Reduced Ciprofloxacin Susceptibility in Salmonella enterica Causing Bloodstream Infctions in Rural Ghana Daniel Eibach, Hassan M. Al-Emran, Denise Myriam Dekker, Ralf Krumkamp, Yaw Adu-Sarkodie, Ligia Maria Cruz Espinoza, Christa Ehmen, Kennedy Boahen, Peter Heisig, Justin Im, Anna Jaeger, Vera von Kalckreuth, Gi Deok Pak, Ursula Panzner, Se Eun Park, Alexander Reinhardt, Nimako Sarpong, Heidi Schütt-Gerowitt, Thomas F. Wierzba, Florian Marks, Jürgen May Clinical Infectious Diseases 62 (Suppl. 1) S32-S36 (2016) |
| 95 |
Detection of a Novel gyrB Mutation Associated with Fluoroquinolone-Nonsusceptible Salmonella enterica serovar Typhimurium Isolated from a Bloodstream Infection in Ghana Hassan M. Al-Emran, Anke Heisig, Denise Dekker, Yaw Adu-Sarkodie, Ligia Maria Cruz Espinoza, Ursula Panzner, Vera von Kalckreuth, Florian Marks, Se Eun Park, Nimako Sarpong, Jürgen May, Peter Heisig Clinical Infectious Diseases 62 (Suppl. 1) S47-S49 (2016) |
2015 | |
| 94 |
Investigation of Antifouling Properties of Surfaces Featuring Zwitterionic α-Aminophosphonic Acid Moieties Natalie Wagner, Phyllis Zimmermann, Peter Heisig, Franziska Klitsche, Wolfgang Maison , Patrick Theato Macromolecular Bioscience 15, 1673-1678 (2015) |
2014 | |
| 93 |
Uncomplicated Urinary Tract Infections and Antibiotic Resistance - Epidemiological and Mechanistic Aspects Bernd Wiedemann, Anke Heisig, Peter Heisig Antibiotics 3, 341-352 (2014) |
| 92 |
Biomimetic PEG-catecholates for stabile antifouling coatings on metal surfaces: Applications on TiO2 and stainless steel Faiza Khalil, Elisa Franzmann, Julian Ramcke, Olga Dakischew, Katrin S. Lips, Alexander Reinhardt, Peter Heisig, Wolfgang Maison Colloids and Surfaces, B: Biointerfaces 117, 185-192 (2014) |
| 91 |
Antibiotikaresistenz - werden unsere Waffen stumpf? Peter Heisig Neue und alte Infektionskrankheiten 199-221 (2014), ISBN 978-3-658-04123-6 , Verlag: Springer Fachmedien, Wiesbaden |
2013 | |
| 90 |
EUCAST expert rules in antimicrobial susceptibility testing R. Leclercq, R. Cantón, D. F. J. Brown, C. G. Giske, Peter Heisig, A. P. MacGowan, J. W. Mouton, P. Nordmann, Arne C. Rodloff, G. M. Rossolini, C.-J. Soussy, M. Steinbakk, T. G. Winstanley, G. Kahlmeter Clinical Microbiology and Infection 19, 141-160 (2013) |
| 89 |
An
improved assay for the detection of alterations in bacterial DNA supercoiling in vivo Mobarak Abu Mraheil, Anke Heisig, Peter Heisig Pharmazie 68, 541-548 (2013) |
2012 | |
| 88 |
Prominence of an O75 clonal group (clonal complex 14) among non-ST131 fluoroquinolone-resistant Escherichia coli causing extraintestinal infections in humans and dogs in Australia Joanne L. Platell, Darren J. Trott, James R. Johnson, Peter Heisig, Anke Heisig, Connie R. Clabots, Brian Johnston, Rowland N. Cobbold Antimicrobial Agents and Chemotherapy 56, 3898-3904 (2012) |
2011 | |
| 87 |
Commonality among Fluoroquinolone-Resistant Sequence Type ST131 Extraintestinal Escherichia coli Isolates from Humans and Companion Animals in Australia Joanne L. Platell, Rowland N. Cobbold, James R. Johnson, Anke Heisig, Peter Heisig, Connie Clabots, Michael A. Kuskowski, Darren J. Trott Antimicrobial Agents and Chemotherapy 55, 3782-3787 (2011) |
| 86 |
Identification of variables for aerobic bacterial density al clinical relevant skin sites Mirja Reichel, Peter Heisig, Günter Kampf Journal of Hospital Infection 78, 5-10 (2011) |
| 85 |
CMY-42, a Novel Plasmid-Mediated CMY-2 Variant AmpC β-Lactamase Moritz Hentschke, Stathis D. Kotsakis, Manuel Wolters, Peter Heisig, Vivi Miriagou, Martin Aepfelbacher Microbial Drug Resistance 17, 165-169 (2011) |
2010 | |
| 84 |
Skin bacteria after chlorhexidine exposure - is there a difference in response to human β-Defensin-3? Mirja Reichel, Anke Heisig, Peter Heisig, Günter Kampf European Journal of Clinical Microbiology & Infectious Diseases 29, 623-632 (2010) |
| 83 |
Vergleich der Wirksamkeit von 89,5 % 1-Propanol bei kurzen Anwendungszeiten mit dem Referenzverfahren der DGHM-Methode für die Hautantiseptik (Comparison between the efficacy of 89,5% 1-propanol in shorter application times and the reference method of the DGHM for skin antisepsis) Mirja Reichel, Peter Heisig, Günter Kampf Hygiene & Medizin 35, 64-69 (2010) |
| 82 |
Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance Nadine-Christine Emrich, Anke Heisig, Will Stubbings, Harald Labischinski, Peter Heisig Journal of Antimicrobial Chemotherapy 65, 2530-2533 (2010) |
| 81 |
Harnwegsinfektionen und Antibiotikaresistenz (Urinary tract infections and antibiotic resistance) Peter Heisig Urologe A. 49, 612-617 (2010) |
| 80 |
Identification of Qnr and aac(6')-1b-cr plasmid-mediated fluoroquinolone resistance determinants in multidrug-resistant Enterobacter spp. isolated from extraintestinal infections in companion animals Justine S. Gibson, Rowland N. Cobbold, Peter Heisig, Hanna E. Sidjabat, Myat T. Kyaw-Tanner, Darren J. Trott Veterinary Microbiology 143, 329-336 (2010) |
| 79 |
Fluoroquinolone resistance mechanisms in multidrug-resistant Escherichia coli isolated from extraintestinal infections in dogs Justine S. Gibson, Rowland N. Cobbold, Myat T. Kyaw-Tanner, Peter Heisig, Darren J. Trott Veterinary Microbiology 146, 161-166 (2010) |
2009 | |
| 78 |
Alcohols for skin antisepsis at clinically relevant skin sites Mirja Reichel, Peter Heisig, Thomas Kohlmann, Günter Kampf Antimicrobial Agents and Chemotherapy 53, 4778-4782 (2009) |
| 77 |
The role of intra- and extragenic compensatory mutations in the suppression of fluoroquinolone resistance in a Salmonella Typhimurium gyrA mutant (D87G) Antje Preisler, Peter Heisig Journal of Antimicrobial Chemotherapy 63, 290-294 (2009) |
| 76 |
Type II topoisomerases-inhibitors, repair mechanisms and mutations Peter Heisig Mutagenesis 24, 465-469 (2009) |
2008 | |
| 75 |
Pitfalls in efficacy testing - how important is the validation of neutralization of chlorhexidine digluconate? Mirja Reichel, Peter Heisig, Günter Kampf Annals of Clinical Microbiology and Antimicrobials 7, 20 (7 pp) (2008) |
| 74 |
Molecular characterization of linezolid resistance in two vancomycin-resistant (VanB) Enterococcus faecium isolates using Pyrosequencing Björn Saager, Holger Rohde , Björn S. Timmerbeil, G. Franke, Werner Pothmann, Joachim Dahlke, Stefanie Scherpe, Ingo Sobottka, Peter Heisig, Matthias-Ansver Horstkotte European Journal of Clinical Microbiology & Infectious Diseases 27, 873-878 (2008) |
| 73 |
Emergence of Linezolid Resistance in a Methicillin Resistant Staphylococcus aureus Strain Moritz Hentschke, Björn Saager, M. A. Horstkotte, Stefanie Scherpe, Manuel Wolters, Hartmut Kabisch, R. Grosse, Peter Heisig, Martin Aepfelbacher , Holger Rohde Infection 36, 85-87 (2008) |
| 72 |
Role of global regulator rma for multidrug efflux-mediated fluoroquinolone resistance in Salmonella Silke Feuerriegel, Peter Heisig Microbial Drug Resistance 14, 259-263 (2008) |
| 71 |
Bacterial Resistance to Antibiotics Peter Heisig Encyclopedia of Molecular Pharmacology 102-106 (2008) |
| 70 |
Characterization of the Quinolone-Gyrase-Interaction Using Docking, Molecular-Dynamics and Site-Directed Mutagenesis Jörn Lenz, Thomas Lemcke, Peter Heisig, Andrew E. Torda -/- Herausgeber: Ulrich H. E. Hansmann, Jan H. Meinke, Sandipan Mohanty, Walter Nadler, Olav Zimmermann From Computational Biophysics to Systems Biology (CBSB08). Proceedings of the NIC Workshop 2008, 40, 289-292 (2008), ISBN 978-3-9810843-6-8 , Verlag: John von Neumann Institute for Computing, Jülich |
2007 | |
| 69 |
Nachweis eines Carbapenem-resistenten Klebsiella-Pneumoniae-Isolats in Norddeutschland Björn S. Timmerbeil, Björn Saager, Stefanie Scherpe, Enno Stürenburg, Peter Heisig Chemotherapie Journal 16, 186-188 (2007) |
| 68 |
Nachweis der antibakteriellen Aktiviät von Chitosan Peter Heisig, Tatjana Claußen, Gerd Mayer GMS Krankenhaushygiene Interdisziplinär 2 (2) 1-7 (2007) |
2006 | |
| 67 |
Role of novel gyrA mutations in the suppression of the fluoroquinolone resistance genotype of vaccine strain Salmonella Typhimurium vacT (gyrA D87G) Antje Preisler, Mobarak Abu Mraheil, Peter Heisig Journal of Antimicrobial Chemotherapy 57, 430-436 (2006) |
| 66 |
Effects of different drying processes on the material properties of bacterial cellulose membranes Christian Clasen , Bano M. Sultanova, Tim Axel Wilhelms, Peter Heisig, Werner-Michael Kulicke Macromolecular Symposia 244 (New Cellulose Products and Composites) 48-58 (2006) |
| 65 |
Wirkungs- und Resistenzmechanismen der β-Lactam-Antibiotika: Penicillin-bindende Proteine, ß-Lactamasen und Signalproteine (Penicillin binding proteins, β-lactamases and signal proteins. Mechanisms of action and resistance of β-lactam antibiotics) Peter Heisig Pharmazie in Unserer Zeit 35, 400-408 (2006) |
| 64 |
Antibakterielle Aktivität der Chitosan-haltigen Wundauflage Chitoskin in vitro (Antibacterial Activity In Vitro of Chitoskin - a Chitosan-Containing Wound Dressing) Tatjana Claußen, Gerd Mayer, Peter Heisig Zeitschrift für Wundauflage 6, 304-308 (2006) |
2005 | |
| 63 |
Hase und Igel: Wettlauf mit resistenten Bakterien (Rabbit and hedgehog: Race with resistant bacteria) Ulrike Holzgrabe, Peter Heisig Pharmazeutische Zeitung 150, 2204-2213 (2005) |
2004 | |
| 62 |
A mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase II Thomas Grüger, John L. Nitiss, Anthony Maxwell, E. Lynn Zechiedrich, Peter Heisig, Siegfried Seeber, Yves Pommier, Dirk Strumberg Antimicrobial Agents and Chemotherapy 48, 4495-4504 (2004) |
| 61 |
Wirkungs- und Resistenzmechanismen: Was ist neu an Ketoliden und Oxazolidinonen? (What's new in ketolides and oxazolidinones? Reactions and resistance mechanisms) Peter Heisig Pharmazie in Unserer Zeit 33, 10-19 (2004) |
2003 | |
| 60 |
Synthesis and antimicrobial activity of tetrodecamycin partial structures Franz F. Paintner, Lars Allmendinger, Gerd Bauschke, Caroline Berns, Peter Heisig Bioorganic & Medicinal Chemistry 11, 2823-2833 (2003) |
| 59 |
Clinically significant borderline resistance of sequential clinical isolates of Klebsiella pneumoniae Florian Wagenlehner, Peter Heisig, Christine Irtenkauf, Frank Notka, Jochen Decker, Norbert Lehn, Hans-Jörg Linde International Journal of Antimicrobial Agents 22, 367-373 (2003) |
| 58 |
Topoisomerase IV mutations in quinolone-resistant Salmonellae selected in vitro Heike Hansen, Peter Heisig Microbial Drug Resistance 9, 25-32 (2003) |
2002 | |
| 57 |
Fluorchinolone: Mechanismen der Resistenzentwicklung Norbert Lehn, Hans-Jörg Linde, Peter Heisig Chemotherapie Journal 11 (Suppl. 20) 15-17 (2002) |
| 56 |
Increase in MICs of ciprofloxacin in vivo in two closely related clinical isolates of enterobacter cloacae Hans-Jörg Linde, Frank Notka, Christine Irtenkauf, Jochen Decker, Jens Wild, Hans-Helmut Niller, Peter Heisig, Norbert Lehn Journal of Antimicrobial Chemotherapy 49, 625-630 (2002) |
| 55 |
Der bakteriellen Antibiotikaresistenz auf der Spur Peter Heisig Medizinische Monatsschrift für Pharmazeuten 25 (1) 1-2 (2002) |
2001 | |
| 54 |
In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus Mechthild Boos, Susanne Mayer, Ansgar Fischer, Karl Köhrer, Sibylle Scheuring, Peter Heisig, Jan Verhoef, Ad C. Fluit, Franz-Josef Schmitz Antimicrobial Agents and Chemotherapy 45, 938-942 (2001) |
| 53 |
Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA Grit Ackermann, Yajarayma J. Tang, Robert Kueper, Peter Heisig, Arne C. Rodloff, Joseph Silva, Stuart H. Cohen Antimicrobial Agents and Chemotherapy 45, 2348-2353 (2001) |
| 52 |
In vitro activities of fluoroquinolones against the spirochete Borrelia burgdorferi Peter Kraiczy, Judith Weigand, Thomas A. Wichelhaus, Peter Heisig, Herbert Backes, Volker Schäfer, Georg Acker, Volker Brade, Klaus-Peter Hunfeld Antimicrobial Agents and Chemotherapy 45, 2486-2494 (2001) |
| 51 |
In vitro activity of sitafloxacin against Clostridium difficile Grit Ackermann, Yajarayma J. Tang, Arne C. Rodloff, Joseph Silva, Stuart H. Cohen, Peter Heisig Journal of Antimicrobial Chemotherapy 47, 722-724 (2001) |
| 50 |
Effect of Gemifloxacin to in vitro Selected Mutants and Field Isolates of Salmonella ssp. with Mutations in gyrA, gyrB, parC and marR Heike Hansen, Wolfgang Rabsch, Peter Heisig Journal of Antimicrobial Chemotherapy 47 (Suppl. 1) 37-37 (2001) |
| 49 |
Wirkungs- und Resistenzmechanismen der Chinolone: Actio und Reactio (Action and reaction: properties and resistance mechanisms of quinolones) Peter Heisig, Bernd Wiedemann Pharmazie in Unserer Zeit 30, 382-393 (2001) |
| 48 |
Inhibitors of bacterial topoisomerases: mechanisms of action and resistance and clinical aspects Peter Heisig Planta Medica 67, 3-12 (2001) |
| 47 |
Topoisomerasen (Topoisomerases) Peter Heisig -/- Herausgeber: Ernst Mutschler, Hartmut Lode, Bernd Wiedemann Medizinische Forschung 12 (Bakterielle und virale Resistenz: Epidemiologie, Mechanismen, klinische Relevanz und therapeutische Konsequenzen) 59-66 (2001), Verlag: Akademie der Wissenschaften und Literatur, Mainz; Schwabe & Co. AG Verlag, Basel Alternativer Quellentitel: Symposium der Akademie der Wissenschaften und der Literatur, Mainz am 3./4. Dezember 1999 |
2000 | |
| 46 |
Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season Mark E. Jones, Daniel F. Sahm, Nele Martin, Sibylle Scheuring, Peter Heisig, Clyde Thornsberry, Karl Köhrer, Franz-Josef Schmitz Antimicrobial Agents and Chemotherapy 44, 462-466 (2000) |
| 45 |
In vivo increase in resistance to ciprofloxacin in Escherichia coli associated with deletion of the C-terminal part of MarR Hans-Jörg Linde, Frank Notka, Michaela Metz, Bernd Kochanowski, Peter Heisig, Norbert Lehn Antimicrobial Agents and Chemotherapy 44, 1865-1868 (2000) |
| 44 |
Chinolonresistenzmechanismen bei grampositiven Kokken Susanne Mayer, Peter Heisig, Franz-Josef Schmitz Der Mikrobiologe 10, 13-16 (2000) |
| 43 |
In vitro activity of gemifloxacin and five other fluoroquinolones against defined isogenic mutants of Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus Ansgar Schulte, Peter Heisig Journal of Antimicrobial Chemotherapy 46, 1037-1038 (2000) |
| 42 |
β-Lactamase expression in Yersinia enterocolitica biovars 1A, 1B and 3 Ingo Stock, Peter Heisig, Bernd Wiedemann Journal of Medical Microbiology 49, 403-408 (2000) |
| 41 |
"Medizinische Mikrobiologie für Pharmazeuten" oder Pharmazeutische Microbiologie ("Medical microbiology for pharmacists" or pharmaceutical microbiology) Peter Heisig, Bernd Wiedemann Medizinische Monatsschrift für Pharmazeuten 23, 173-175 (2000) |
| 40 |
Chinolonantibiotika - Wirkungsweise und Resistenzmechanismen (Chinolone antibiotics. Mode of action and resistance mechanisms) Susanne Mayer, Franz-Josef Schmitz, Peter Heisig MTA 15, 77-80 (2000) |
| 39 |
PCR in der medizinischen und pharmazeutischen Analytik Peter Heisig -/- Herausgeber: Oliver Kayser, Rainer H. Müller Pharmazeutische Biotechnologie 225-238 (2000), Verlag: Wissenschaftliche Verlagsgesellschaft, Stuttgart |
| 38 |
Classification of bacteria using sequences of gyr and par genes Peter Heisig, Yolanda Fuchs-Gomez Patent: WO 2000061796 (A1) 2000-10-19 |
1999 | |
| 37 |
Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linezolid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains Mark E. Jones, Maarten R. Visser, Miriam Klootwijk, Peter Heisig, Jan Verhoef, Franz-Josef Schmitz Antimicrobial Agents and Chemotherapy 43, 421-423 (1999) |
| 36 |
Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli Simone Bagel, Volker Hüllen, Bernd Wiedemann, Peter Heisig Antimicrobial Agents and Chemotherapy 43, 868-875 (1999) |
| 35 |
Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones Sylvain Brisse, Ad C. Fluit, Ulrich Wagner, Peter Heisig, Dana Milatovic, Jan Verhoef, Sibylle Scheuring, Karl Köhrer, Franz-Josef Schmitz Antimicrobial Agents and Chemotherapy 43, 2513-2516 (1999) |
| 34 |
Bakterielle
Resistenz gegenüber Chinolonen (Bacterial resistance to quinolones (ciprofloxacin)) Bernd Wiedemann, Peter Heisig Chemotherapie Journal 8, 99-107 (1999) |
| 33 |
The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus Holger Schedletzky, Bernd Wiedemann, Peter Heisig Journal of Antimicrobial Chemotherapy 43 (Suppl. B) 31-37 (1999) |
| 32 |
Expression of β-lactamases in Yersinia enterocolitica strains of biovars 2, 4, and 5 Ingo Stock, Peter Heisig, Bernd Wiedemann Journal of Medical Microbiology 48, 1023-1027 (1999) |
| 31 |
Neue 4-Chinolonderivate im Überblick (New 4-quinolone derivatives. An overview) Ulrike Holzgrabe, Peter Heisig Pharmazie in Unserer Zeit 28, 30-35 (1999) Erratum: Pharmazie in Unserer Zeit 28, 285-285 (1999) |
| 30 |
DNA als Arzneistoff (Application of DNA as drug) Peter Heisig Pharmazie in Unserer Zeit 28, 130-137 (1999) |
| 29 |
Mechanisms of antibiotic resistance in Gram-negative bacteria of clinical importance Peter Heisig Nova Acta Leopoldina 78 (307, Problems of Relevant Infectious Diseases) 257-267 (1999), ISBN 978-3-335-00618-3; 3-335-00618-6 |
1997 | |
| 28 |
Fluorchinoloncarbonsäuren - moderne antibakterielle Chemotherapeutika mit breitem Wirkungsspektrum Peter Heisig Arzneimitteltherapie 15, 14-23 (1997) |
| 27 |
Mechanisms and epidemiology of fluoroquinolone resistance in Enterobacteriaceae Peter Heisig BIOspektrum Sonderband (Antibiotic resistance: recent developments and future perspectives : mechanisms and spread : new targets for antimicrobial agents) 42-46 (1997) |
| 26 |
GyrA Mutationen bei fluorchinolonresistenten Enterobakterien L. Y. Fuchs, C. Diaz, Barbara Kratz, Peter Heisig Chemotherapie Journal 6, 56-57 (1997) |
| 25 |
Antibacterial activity of grepafloxacin Bernd Wiedemann, Peter Heisig Journal of Antimicrobial Chemotherapy 40 (Suppl. A) 19-25 (1997) |
| 24 |
Verbreitung und Mechanismen der Resistenz gegenüber Fluorchinolonen Peter Heisig, Norbert Lehn Symposium MEDICAL 8 (3) 16-17 (1997) |
| 23 |
Mechanismen und Epidemiologie hoher Fluorchinolonresistenz bei Escherichia coli und anderen Gram-negativen Bakterien Peter Heisig Habilitationsschrift, Bonn (1997) |
1996 | |
| 22 |
Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli Peter Heisig Antimicrobial Agents and Chemotherapy 40, 879-885 (1996) |
| 21 |
Synthesis and biological activities of new N1-aryl substituted quinolone antibacterials Jens Jürgens, Holger Schedletzky, Peter Heisig, Joachim K. Seydel, Bernd Wiedemann, Ulrike Holzgrabe Archiv der Pharmazie 329, 179-190 (1996) |
| 20 |
Klinische Fluorchinolonresistenz bei E.coli (Chemical fluoroquinolone resistance of Escherichia coli: importance of gyrA-mutation on the serine-83 codon) Peter Heisig, Daniela Olsoczki, Norbert Lehn, Bernd Wiedemann Chemotherapie Journal 5, 185-188 (1996) |
1995 | |
| 19 |
Identification of DNA Gyrase A mutations in ciprofloxacin resistant isolates of Salmonella typhimurium from men and cattle in Germany Peter Heisig, Barbara Kratz, Elke Halle, Yvonne Gräser, Martin Altwegg, Wolfgang Rabsch, Jakob-Peter Faber Microbial Drug Resistance 1, 211-218 (1995) |
1994 | |
| 18 |
Characterization of fluoroquinolone-resistant mutants of Escherichia coli selected in vitro Peter Heisig, Regina Tschorny Antimicrobial Agents and Chemotherapy 38, 1284-1291 (1994) |
| 17 |
Mechanismen bakterieller Resistenz gegen Antibiotika Peter Heisig Arzneimitteltherapie 12, 203-218 (1994) |
| 16 |
Mechanisms of Quinolone Resistance Bernd Wiedemann, Peter Heisig Infection 22 (Suppl. 2) S73-S79 (1994) |
| 15 |
Clinical significance and spread of fluoroquinolone resistant uropathogens in hospitalised urological patients Kurt Georg Naber, Florian Wagenlehner, Wolfgang Witte, Ingo Klare, Adolf Bauernfeind, Bernd Wiedemann, Peter Heisig Infection 22 (Suppl. 2) S122-S127 (1994) |
| 14 |
Quinolone-Resistance in Gram-Negative Bacteria Bernd Wiedemann, Peter Heisig Infectious Diseases in Clinical Practice 3 (Suppl. 3) S115-S126 (1994) |
| 13 |
Ciprofloxacin resistance in enterobacterial clinical isolates Peter Heisig, L. Tsouvelekis, A. Vatopoulos, Nicolas Legakis Journal of Antimicrobial Chemotherapy 33, 887-888 (1994) |
| 12 |
Adenylylsulfate reductase from the sulfate-reducing archaeon Archaeoglobus fulgidus: cloning and characterization of the genes and comparison of the enzyme with other iron-sulfur flavoproteins Norbert Speich, Christiane Dahl, Peter Heisig, Albrecht Klein, Friedrich Lottspeich, Karl O. Stetter, Hans-G. Trüper Microbiology 140, 1273-1284 (1994) |
1993 | |
| 11 |
Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli Peter Heisig, Holger Schedletzky, Hildegard Falkenstein-Paul Antimicrobial Agents and Chemotherapy 37, 696-701 (1993) |
| 10 |
GyrA-Mutationen bei chinolonresistenten E. coli Peter Heisig, Holger Schedletzky, Hildegard Falkenstein-Paul Chemotherapie Journal 2, 18-23 (1993) |
| 9 |
High-level fluoroquinolone resistance in a Salmonella typhimurium isolate due to alterations in both gyrA and gyrB genes Peter Heisig Journal of Antimicrobial Chemotherapy 32, 367-377 (1993) |
| 8 |
Fluorierte Chinolon-Carbonsäuren: Wird der Fortschritt durch die Resistenzentwicklung aufgehoben? (Fluorinated quinolone carbonic acids. Are advances stopped by drug resistance development?) Bernd Wiedemann, Peter Heisig Pharmazie in Unserer Zeit 22, 286-295 (1993) |
1991 | |
| 7 |
Use of a broad-host-range gyrA plasmid for genetic characterization of fluoroquinolone-resistant Gram-negative bacteria Peter Heisig, Bernd Wiedemann Antimicrobial Agents and Chemotherapy 35, 2031-2036 (1991) |
| 6 |
Beurteilung der Resistenzentwicklung als Faktor für die Einschränkung therapeutischer Möglichkeiten Peter Heisig, Bernd Wiedemann Infection 19 (Suppl. 1) S47-S51 (1991) |
| 5 |
Genetische Grundlagen und Verbreitung von Fluorchinolonresistenz Peter Heisig, Bernd Wiedemann Fortschritte der Antimikrobiellen und Antineoplastischen Chemotherapie 10 (3) 223-232 (1991), Verlag: Paul-Ehrlich-Gesellschaft für Chemotherapie |
1989 | |
| 4 |
Comparison of the antimicrobial activity of cefuroxime with other oral antibiotics Bernd Wiedemann, Peter Heisig Journal of Chemotherapy Suppl. 4, 93-96 (1989) |
| 3 |
Bakterielle Resistenz gegen 4-Chinolone: Mechanismus und Bedeutung (Bacterial resistance to 4-quinolones: mechanisms and importance) Peter Heisig, Bernd Wiedemann Fortschritte der Antimikrobiellen und Antineoplastischen Chemotherapie 8 (1) 5-14 (1989), Verlag: Paul-Ehrlich-Gesellschaft für Chemotherapie |
1987 | |
| 2 |
Das mom-Gen des Bakteriophagen Mu Peter Heisig -/- Betreuer: Thomas A. Trautner, Bernd Wiedemann, Regine Kahmann Dissertation, Bonn (1987) |
1986 | |
| 1 |
The sequence and mom-transactivation function of the C gene of bacteriophage Mu Peter Heisig, Regine Kahmann Gene 43, 59-67 (1986) |